Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression - Scorecard - MDSpire

Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression

  • By

  • Faezeh Ghazvini Zadegan

  • Clara Stanko

  • Franziska Fiedler

  • Laura Ölsner

  • Setenay Gupse Özcan

  • Jacqueline Schütt

  • Tina M. Schnöder

  • Yordan Sbirkov

  • Lukasz Szymanski

  • Sven Stengel

  • Peter Dittrich

  • Jörg P. Müller

  • Florian H. Heidel

  • Andreas Hochhaus

  • Sebastian Scholl

  • Ulf Schnetzke

  • Annamaria Brioli

  • Tino Schenk

  • June 27, 2026

  • 0 min

Share

Clinical Scorecard: Tamibarotene (Am80) and ATRA Trigger Comparable Molecular Changes and Myeloid Differentiation in Non-APL AML, Enhanced by Inhibition of LSD1/GCN5 and Elevated RARA Levels

At a Glance

CategoryDetail
ConditionAcute Myeloid Leukemia (AML)
Key MechanismsRegulated by retinoic acid receptor (RAR) transcription factors, particularly RARA and RARG, influencing myeloid differentiation.
Target PopulationPatients with non-APL AML, particularly those with high RARA expression.
Care SettingClinical trials and laboratory research.

Key Highlights

  • Am80 is more potent than ATRA in inducing differentiation in RARA-high AML.
  • Inhibition of LSD1 and GCN5 enhances ATRA and Am80 responses.
  • High RARA expression correlates with better treatment outcomes in AML patients.

Guideline-Based Recommendations

Diagnosis

  • Assess RARA expression levels in AML patients.

Management

  • Consider Am80 for patients with high RARA expression.

Monitoring & Follow-up

  • Monitor differentiation markers and response to treatment.

Risks

  • Evaluate potential resistance mechanisms involving LSD1 and GCN5.

Patient & Prescribing Data

Patients with non-APL AML, especially those with elevated RARA levels.

Combination of Am80 with azacytidine shows improved responses in clinical trials.

Clinical Best Practices

  • Utilize RARA-selective agonists like Am80 in RARA-overexpressing AML.
  • Incorporate epigenetic inhibitors to enhance retinoid therapy.

Related Resources & Content

Original Source(s)

Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression

  • by Faezeh Ghazvini Zadegan, Clara Stanko, Franziska Fiedler, Laura Ölsner, Setenay Gupse Özcan, Jacqueline Schütt, Tina M. Schnöder, Yordan Sbirkov, Lukasz Szymanski, Sven Stengel, Peter Dittrich, Jörg P. Müller, Florian H. Heidel, Andreas Hochhaus, Sebastian Scholl, Ulf Schnetzke, Annamaria Brioli, Tino Schenk

  • June 27, 2026

Related Content

Genome-wide association study identifies and validates genetic variation in the RIG-I/MAVS signaling pathway associated with HIV-related Kaposi sarcoma in children and adults

Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer

Hemorrhage-coagulation immune phenotype is associated with CD163/HO-1-enriched heme-processing macrophage remodeling and predicts recurrence in colorectal cancer: a real-world retrospective cohort study